PrismaLuc luciferase enables tunable near-infrared bioluminescence for in vivo imaging
4 affiliations
- 1Department of Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Centre Rotterdam The Netherlands
- 2Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Centre Rotterdam The Netherlands
- 3Promega Corporation Madison Wisconsin USA
- 4Delft University of Technology, Delft The Netherlands
Abstract
Bioluminescence imaging (BLI) enables non-invasive monitoring of biological processes in living animals, yet most bioluminescent reporters emit at fixed wavelengths with limited spectral flexibility, constraining their use in multiplexed and deep-tissue applications. Bioluminescence resonance energy transfer (BRET) offers a solution by coupling a luciferase to a proximal fluorescent protein or synthetic fluorophore that absorbs the emitted light and re-emits it at a longer wavelength. However, existing BRET systems built from luciferase–fluorescent protein fusions are limited by suboptimal energy transfer efficiency and the fixed photophysical properties of their genetically encoded chromophores. We recently introduced PrismaLuc, a high-efficiency BRET reporter, in which a circularly permuted NanoLuc is inserted into HaloTag, enabling efficient energy transfer to a covalently bound synthetic fluorophore whose emission wavelength is selected by choice of ligand. In our initial report, PrismaLuc was paired with JF549 HaloTag ligand for two-colour cell-based assays. Here, we extend PrismaLuc to in vivo bioluminescence imaging using far-red and near-infrared HaloTag ligands. In cultured cells, labelling with JF608 and JF669 HaloTag ligands produced emission peaks at 640 and 690 nm, respectively. Direct comparison with established BRET reporters revealed greater photon output at wavelengths above 665 nm, which are less attenuated in tissue. In tumour-bearing mice, PrismaLuc:JF669 produced an emission peak of approximately 700 nm, and in vivo fluorescence imaging confirmed sufficient JF669 HaloTag ligand bioavailability to label PrismaLuc expressed in xenograft tumours. Finally, dual-colour imaging in mice co-implanted with NanoLuc- and PrismaLuc-expressing cells demonstrated clear spectral separation, enabling multiplexed detection within the same animal. Together, these results establish PrismaLuc as a tunable platform for near-infrared and dual-colour bioluminescence imaging in vivo.
Related
- ATP-free fatty aldehyde biosynthesis enables an autonomous lux-based bioluminescence system
- Shedding light on Gaussia Luciferase conformational space using multi-conformation enhanced sampling simulation
- Quantitative Bioluminescent Imaging of AHR Activity Using a Thermostable Variant of the Fungal Luciferase nnLuz
- Biochemical characterisation of fungal bioluminescence enzymes reveals substrate inhibition and secondary turnover of 3-hydroxyhispidin by H3H
- Unveiling bioluminescence: understanding mechanisms and exploring wide-ranging applications
BibTeX
@article{gamafranceschi2026prismaluc,
title = {{PrismaLuc luciferase enables tunable near-infrared bioluminescence for in vivo imaging}},
author = {Felipe Gama-Franceschi and Rachel Friedman Ohana and Chao Gao and Thomas Kirkland and Laura Mezzanotte},
journal = {RSC Chemical Biology},
year = {2026},
month = sep,
doi = {10.1039/d6cb00175k},
url = {https://doi.org/10.1039/d6cb00175k},
note = {CC BY 3.0},
}
RIS
TY - JOUR
TI - PrismaLuc luciferase enables tunable near-infrared bioluminescence for in vivo imaging
AU - Felipe Gama-Franceschi
AU - Rachel Friedman Ohana
AU - Chao Gao
AU - Thomas Kirkland
AU - Laura Mezzanotte
PY - 2026
DA - 2026/09/07
JO - RSC Chemical Biology
DO - 10.1039/d6cb00175k
UR - https://doi.org/10.1039/d6cb00175k
AB - Bioluminescence imaging (BLI) enables non-invasive monitoring of biological processes in living animals, yet most bioluminescent reporters emit at fixed wavelengths with limited spectral flexibility, constraining their use in multiplexed and deep-tissue applications. Bioluminescence resonance energy transfer (BRET) offers a solution by coupling a luciferase to a proximal fluorescent protein or synthetic fluorophore that absorbs the emitted light and re-emits it at a longer wavelength. However, existing BRET systems built from luciferase–fluorescent protein fusions are limited by suboptimal energy transfer efficiency and the fixed photophysical properties of their genetically encoded chromophores. We recently introduced PrismaLuc, a high-efficiency BRET reporter, in which a circularly permuted NanoLuc is inserted into HaloTag, enabling efficient energy transfer to a covalently bound synthetic fluorophore whose emission wavelength is selected by choice of ligand. In our initial report, PrismaLuc was paired with JF549 HaloTag ligand for two-colour cell-based assays. Here, we extend PrismaLuc to in vivo bioluminescence imaging using far-red and near-infrared HaloTag ligands. In cultured cells, labelling with JF608 and JF669 HaloTag ligands produced emission peaks at 640 and 690 nm, respectively. Direct comparison with established BRET reporters revealed greater photon output at wavelengths above 665 nm, which are less attenuated in tissue. In tumour-bearing mice, PrismaLuc:JF669 produced an emission peak of approximately 700 nm, and in vivo fluorescence imaging confirmed sufficient JF669 HaloTag ligand bioavailability to label PrismaLuc expressed in xenograft tumours. Finally, dual-colour imaging in mice co-implanted with NanoLuc- and PrismaLuc-expressing cells demonstrated clear spectral separation, enabling multiplexed detection within the same animal. Together, these results establish PrismaLuc as a tunable platform for near-infrared and dual-colour bioluminescence imaging in vivo.
SN - 2633-0679
ER -